Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa

Abstract

We have investigated whether the potential benefits of a controlled release formulation of levodopa (200 mg)/carbidopa (50 mg), Sinemet CR, are realised during maintenance therapy. Eight sufferers from idiopathic Parkinsonism, mean age 69.9 y, were studied: all exhibited "end of dose" effect within 4 h of a dose of their maintenance therapy with levodopa (100 mg)/carbidopa (25 mg) in a conventional release formulation, Sinemet Plus. They received, in random order, initial single dose challenges with one tablet of Sinemet Plus, one and two tablets of Sinemet CR and placebo alone, each on a separate day. After a mean of 21 weeks on maintenance therapy with Sinemet CR, subsequent single dose challenges with Sinemet CR and placebo were made. Objective measures of performance and blood sampling for assay of plasma concentrations of levodopa and the major peripheral metabolite, 3-0-methyldopa (30MD) were carried out immediately before (10.00 h) and serially until 6 h after each challenge. The overall mean stride length was significantly greater in relation to the subsequent (679 mm) than the initial (517 mm) placebo challenge. Moreover, stride length immediately before the challenges was significantly greater on the subsequent occasions. Improved performance, also seen for free walking speed, was not explained by plasma levodopa or 30MD concentrations. In the initial challenges, the mean increment in stride length achieved by active treatment, as compared with placebo, did not differ significantly between the one (210 mm) and two (235 mm) tablet doses of Sinemet CR: a maximal response had been obtained.(ABSTRACT TRUNCATED AT 250 WORDS)

Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study

“…Statistical modelling of observational data is used to generate hypotheses. Having found subjective global clinical scores to be blunt instruments [55], we have embraced valid, sensitive, specific and reliable measures of disease facets. To avoid incorrect inferences, we endeavour to understand what is being measured, its variability and what influences it (i.e.…”

Helicobacter Hypothesis for Idiopathic Parkinsonism: Before and Beyond

“…a They allow economy in sample size; give clarity in defining differential time trends between disease facets; and allow pre-and post-presentational states to be considered as a continuum, in a disease widely accepted as having a long prodrome. Global scores, and even relevant subscores, are relatively insensitive to intervention [101]: adding in the immutable can mask important changes. sees IP as evolving from the gastrointestinal tract [9], but readers seize upon just one mechanism, migration along neural pathways.)…”

Defining small differences in efficacy between anti‐parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.

“…The sensitivity of distance/time measures of gait, in detecting anti-Parkinsonian treatment effects, has been demonstrated in sufferers without overt 'on/off' fluctuations in performance in relation to individual doses of medication (Bowes et al, 1991). Gait analysis has also proved a powerful tool in detecting changes in responsiveness to medication with duration of therapy, in those with overt fluctuations (Bowes et al, 1992a).…”